FDA approved belzutifan (Welireg®) + lenvatinib (Lenvima®) on Sept 28 for advanced clear cell RCC after PD-1/PD-L1 therapy: the first HIF-2α inhibitor + VEGFR-TKI combo for these patients.
#KidneyCancer #RCC #Oncology #ChinaOnlinePharmacy
FDA approved belzutifan (Welireg®) + lenvatinib (Lenvima®) on Sept 28 for advanced clear cell RCC after PD-1/PD-L1 therapy: the first HIF-2α inhibitor + VEGFR-TKI combo for these patients.
#KidneyCancer #RCC #Oncology #ChinaOnlinePharmacy
On Sept 25, 2026, the FDA approved baricitinib (Olumiant) for patients aged 12+ with severe alopecia areata.
A new option for teens. 🎉
#AlopeciaAreata #FDA #Dermatology #ChinaOnlinePharmacy
On Sept 25, 2026, the FDA approved baricitinib (Olumiant) for patients aged 12+ with severe alopecia areata.
A new option for teens. 🎉
#AlopeciaAreata #FDA #Dermatology #ChinaOnlinePharmacy
#TravelChina #ChinaTravelTips #ExpatLife #ChinaOnlinePharmacy
#TravelChina #ChinaTravelTips #ExpatLife #ChinaOnlinePharmacy